glp-1 in europe Weight Loss Europe: Eligibility, Costs & Access GLP-1 agonists may interfere with

Sarcopenia, or age-related muscle loss, can lead to decreased physical function, increased risk of falls and fractures, higher susceptibility to chronic diseases, and negative impacts on mental health if left unaddressed

Results from the FIGHT trial did not support the use of liraglutide in HF patients, which is not surprising given less clear-cut HF benefits in NMA compared to SGLT2 inhibitors.17,54 The on-going EGRABIS1 (NCT02829502) and Lirabolic (NCT04057261) trials also aim to explore the effects of GLP-1 RAs on cardiometabolic markers, such as mean cerebral flow velocity, as well as BP and lipid profiles

Penn study finds taking semaglutide for weight management does not increase risk of depression or suicidal behavior in people without known major psychopathology

We need to monitor patients closely

As interest in GLP-1 medication grows, scammers are tricking consumers with fake alternatives

predominantly in -cells (~80% of the islet population), non -cells (~20%) also express GLP1R (-and (~12%) and -cells), lung, stomach, heart, ovary, kidney, 3T3-L1 preadipocytes and in mouse and human mature adipocytes, also in human epicardial fat and in visceral and subcutaneous adipose tissue [46,57,58,59,60,61,62,63,64,65,66]